Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / BPC-157
Not FDA-approvedInsufficient
BPC-157
ALSO KNOWN ASBody protection compound 157
A heavily marketed repair peptide whose human evidence does not support the confidence of the claims.
01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEMarketed as injectable, oral, nasal and topical products; none is approved
04REVIEW STANDARDProduct, indication and evidence
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What BPC-157 is.
A synthetic 15-amino-acid peptide derived from a sequence described in gastric juice research. Most tendon, ligament, gut and wound-healing claims trace to cell or animal models rather than controlled human trials.
HOW IT IS THOUGHT TO WORK
Proposed effects involve angiogenesis, nitric-oxide signaling, inflammation and tissue repair, but the relevance and safety of these pathways in humans remain uncertain.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established clinical benefit for tendon, ligament, muscle or gut healing
- Preclinical findings have generated hypotheses, not a validated treatment
- Faster sports-injury recovery
- Healing of tendons or ligaments in humans
- Safe treatment of inflammatory bowel disease
- A safe oral or injectable dose
Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Research interest does not establish an approved treatment, a safe personal regimen or reliable product quality. Discuss established alternatives with a qualified clinician.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- There is no validated lab panel that establishes safety
- A sports injury still requires diagnosis, load management and rehabilitation
SAFETY
Risks, red flags and reasons to avoid it.
- Unknown human toxicity and reproductive effects
- Immunogenicity, aggregation and peptide-related impurities
- Contamination, incorrect identity and dosing error
- Theoretical concern when manipulating angiogenic pathways
- Self-injection
- Pregnancy or fertility treatment
- Active cancer
- Using it to delay evaluation of a serious injury or GI disease
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
01
FDA evidence reviewFDA 2026 BPC-157 briefing document
↗02Peer-reviewed review2026 orthopaedic peptide evidence review
↗03Human pilotHuman IV pilot: 10 mg then 20 mg in two adults
↗04Market practice — not guidelineExample clinic-reported 250–500 mcg practice range
↗05FDA safetyFDA peptide compounding safety risks
↗PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Sold online and by some clinics despite no FDA-approved BPC-157 drug. FDA has proposed not adding BPC-157 substances to the 503A bulks list after reviewing limited evidence and safety concerns.
BPC-157 is a prime example of marketing moving faster than human evidence. Testimonials cannot establish purity, dose, healing or long-term safety.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP